This is a material pipeline expansion for ORKA-001 into IBD, a large and competitive market with established IL-23 blockbusters (Skyrizi, Stelara). The dosing restrictions create a clear timeline catalyst: watch for IND filings or Phase I starts in IBD after June 2028. The change-of-control acceleration clause also makes Oruka a more attractive M&A target.
Price Chart
Executive Summary
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include inflammatory bowel disease (IBD), removing a key restriction on ORKA-001's addressable market. The amendment imposes dosing restrictions (no monotherapy IBD dosing until June 2030, no combination dosing until June 2028), but these accelerate to June 2028 upon a material transaction like a change of control. This significantly expands the commercial opportunity for ORKA-001, a $3.5B market cap biotech's lead asset.
Key Facts
- Oruka expanded the field of use for its IL-23 license to include all therapeutic areas, including inflammatory bowel disease (IBD), which was previously excluded.
- Monotherapy dosing of ORKA-001 for IBD is restricted until June 1, 2030; combination dosing until June 1, 2028.
- Upon a material transaction (change of control or sale of Phase II-stage assets), the monotherapy restriction accelerates to June 1, 2028.
- Paragon granted Oruka exclusivity in the IBD field until October 11, 2029, and Oruka granted Paragon a non-exclusive cross-license for retained antibodies outside IBD.
- The amendment was signed May 29, 2026, and filed June 1, 2026.
Financial Impact
No financial terms disclosed; the amendment expands the addressable market for ORKA-001 to include IBD, a multi-billion-dollar therapeutic area.
Risk Factors
- IBD market is highly competitive with approved IL-23 inhibitors (Skyrizi, Stelara, Tremfya) — ORKA-001 must differentiate on efficacy, safety, or dosing.
- Dosing restrictions delay IBD clinical development until at least 2028, limiting near-term value inflection.
- No financial consideration disclosed — the amendment's value depends entirely on ORKA-001's clinical profile in IBD, which is unproven.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063481 |
| Document: ea029287601ex10-1.htm | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index-headers.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481-index.html | 0001213900-26-063481 |
| Document: 0001213900-26-063481.txt | 0001213900-26-063481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access